EPZ5676: Potent and Selective DOT1L Inhibitor for MLL-Rearranged Leukemia Research

Executive Summary: EPZ5676 is a SAM-competitive inhibitor targeting DOT1L with an IC50 of 0.8 nM and Ki of 80 pM, demonstrating >37,000-fold selectivity over other methyltransferases [APExBIO product page]. It induces robust inhibition of H3K79 methylation and downregulates MLL-fusion target genes, leading to potent cytotoxicity in MLL-rearranged leukemia cell lines (Anbazhagan et al., 2024). In vivo, EPZ5676 causes complete regression of MV4-11 xenografts at doses between 35–70 mg/kg/day without significant toxicity. Its high solubility in DMSO and ethanol, but not water, defines key handling parameters. EPZ5676 is supplied by APExBIO and is recommended for biochemical and cellular studies of epigenetic regulation in cancer.

Biological Rationale

DOT1L (Disruptor of Telomeric Silencing 1-Like) is a histone methyltransferase responsible for methylation of histone H3 at lysine 79 (H3K79). This mark is associated with active gene transcription. In MLL-rearranged leukemias, DOT1L-mediated H3K79 methylation is critical for the expression of leukemogenic target genes. Inhibition of DOT1L suppresses these gene networks, impeding leukemia cell proliferation and survival (Anbazhagan et al., 2024). Epigenetic modifications, such as H3K79 methylation, are increasingly recognized as therapeutic targets in cancer and are central to the mechanism of action of EPZ5676. Recent studies show that methyltransferase activity is context-dependent, with cross-talk between DOT1L and other histone-modifying enzymes, including HDAC family members [Related: Mechanistic Insights]. This article extends the focus by detailing the selectivity profile, application parameters, and translational benchmarks of EPZ5676, enabling precision targeting in leukemia models.

Mechanism of Action of DOT1L inhibitor EPZ-5676

EPZ5676 is a small molecule that selectively and potently inhibits DOT1L by occupying the S-adenosyl methionine (SAM) binding pocket. This competitive inhibition induces conformational changes, exposing a hydrophobic pocket beyond the amino acid moiety of SAM [APExBIO]. Its IC50 for DOT1L is 0.8 nM, and its Ki is 80 pM, indicating extremely high affinity. The selectivity is >37,000-fold compared to other methyltransferases such as CARM1, EHMT1/2, EZH1/2, PRMT family, SETD7, SMYD2/3, and WHSC1/1L1, minimizing off-target effects [Related: Epigenetic Precision]. By blocking DOT1L activity, EPZ5676 effectively inhibits H3K79 methylation, leading to transcriptional downregulation of MLL-fusion oncogenes and induction of apoptosis in susceptible leukemia cells.

Evidence & Benchmarks

• EPZ5676 inhibits DOT1L with an IC50 of 0.8 nM and Ki of 80 pM, exhibiting >37,000-fold selectivity versus other methyltransferases (APExBIO).
• In MV4-11 acute leukemia cell lines, antiproliferative activity is observed with an IC50 of 3.5 nM after 4–7 days of exposure (Anbazhagan et al., 2024).
• In vivo, intravenous administration of EPZ5676 (35–70 mg/kg/day for 21 days) to nude rats bearing MV4-11 xenografts leads to complete tumor regression without significant weight loss or toxicity (Anbazhagan et al., 2024).
• EPZ5676 is highly soluble in DMSO (≥28.15 mg/mL) and ethanol (≥50.3 mg/mL, ultrasonic assistance), but insoluble in water (APExBIO).
• DOT1L inhibition by EPZ5676 leads to downregulation of H3K79 methylation, suppression of MLL-fusion target gene expression, and induction of apoptosis in MLL-rearranged leukemic cells (Anbazhagan et al., 2024).

Applications, Limits & Misconceptions

EPZ5676 is primarily used in biochemical enzyme inhibition assays, cell proliferation assays, and in vivo xenograft models for preclinical research on MLL-rearranged leukemia. It is not a pan-methyltransferase inhibitor and demonstrates negligible activity against non-DOT1L enzymes. Its robust selectivity profile makes it highly suitable for dissecting DOT1L-specific pathways in cancer epigenetics.

This article extends on DOT1L Inhibition and Epigenetic Precision by detailing practical workflow integration and emphasizing the compound's storage, solubility, and selectivity. For novel antifibrotic and translational oncology applications, see DOT1L Inhibitor EPZ-5676 in Translational Fibrosis and Oncology, which is complemented here by detailed experimental parameters and benchmarking data. For guidance on troubleshooting and workflow optimization, DOT1L Inhibitor EPZ5676: Precision Tool for MLL Leukemia offers context that is further refined in this article by explicit selectivity and storage data.

Common Pitfalls or Misconceptions

• EPZ5676 is not suitable for inhibiting other histone methyltransferases beyond DOT1L due to its high selectivity.
• The compound is insoluble in water; improper dissolution protocols can result in precipitation or loss of activity.
• Long-term storage of solutions, especially at temperatures above -20°C, can result in compound degradation.
• Short exposure (<24 h) may not yield maximal antiproliferative effects; typical assays require 4–7 days of treatment.
• EPZ5676 is a research tool and not approved for clinical use in humans.

Workflow Integration & Parameters

For in vitro applications, dissolve EPZ5676 in DMSO at concentrations up to ≥28.15 mg/mL, or in ethanol (≥50.3 mg/mL with ultrasonic assistance). For cell-based assays, typical working concentrations range from 1–10 nM for sensitive cell lines such as MV4-11. For in vivo rodent models, intravenous doses of 35–70 mg/kg/day for 21 days have been validated. Stock solutions should be stored below -20°C, with aliquots to minimize freeze-thaw cycles. Avoid prolonged storage of working solutions, and ensure solutions are prepared fresh for each experiment. For biochemical enzyme inhibition assays, use buffers compatible with DMSO concentrations up to 1% to maintain compound solubility and stability. The product is available as a solid through APExBIO (DOT1L inhibitor EPZ-5676 A4166).

Conclusion & Outlook

EPZ5676 sets the benchmark for DOT1L inhibition in epigenetic and leukemia research, combining exceptional potency, selectivity, and in vivo efficacy. Its precise targeting of H3K79 methylation and compatibility with diverse experimental workflows enable robust exploration of MLL-rearranged leukemia mechanisms and preclinical therapeutic strategies. Further research is encouraged to extend its application to additional models of epigenetic dysregulation and to explore synergistic approaches with other modulators of chromatin dynamics. For a comprehensive mechanistic view and troubleshooting strategies, see EPZ5676: Potent DOT1L Inhibitor Transforming Leukemia Research, which this article augments with new benchmarks and storage guidelines.